AHA Issues Deprescribing Roadmap for Cardiovascular Care

The American Heart Association (AHA) has issued a new scientific statement providing a roadmap for identifying and safely deprescribing unnecessary medications in patients with cardiovascular disease and polypharmacy. Published in Circulation on 21 July 2026, the statement addresses one of the most persistent quality-of-care and drug utilisation challenges in cardiology, where roughly 60% of cardiovascular patients (and up to three-quarters of heart failure patients) take five or more medications simultaneously.

Polypharmacy contributes to adverse drug events, poor medication adherence and increased hospitalisation rates, all of which weigh on cardiovascular outcomes and healthcare costs. The statement, chaired by Robert J. DiDomenico, PharmD, FAHA, identifies four patient groups warranting closer evaluation: those experiencing adverse drug events, those with polypharmacy or hyperpolypharmacy, those with prescribing cascades, and those receiving palliative or end-of-life care. It positions accurate medication reconciliation as the essential starting point, and points clinicians to established tools such as the Beers criteria and STOPP/START to flag potentially inappropriate medications. Shared decision-making with patients is highlighted as critical to preserving trust.

The statement also addresses paediatric cardiovascular populations, an area historically under-represented in polypharmacy research. On the implementation side, the AHA points to newly announced CMS billing codes designed to support deprescribing services in clinical practice, alongside persistent gaps that continue to constrain scale-up: limited outcomes data, patchy reimbursement pathways and insufficient inclusion of deprescribing content in health professions education. The commercial implications sit across cardiovascular drug utilisation, pharmacy services, managed care and PBM approaches, at a moment when payer scrutiny of drug spend and appropriateness is intensifying.

The commercial signal is a convergence of clinical guidance, payer policy and pharmacist workflow around deprescribing at exactly the moment cardiovascular drug spend and appropriateness are under intensifying scrutiny. With CMS billing codes coming online and the AHA framework in circulation, expect expanded deprescribing programmes across integrated delivery networks, health plans and community pharmacy chains such as CVS Health, Walgreens and Kroger Health.

For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Katie Ginger today!